Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)

NCT01267240 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01267240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01267240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2010
Completion date
October 31, 2016
Enrollment
25 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

paranasal sinus squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iva hypopharyngeal squamous cell carcinoma, stage iva laryngeal squamous cell carcinoma, stage iva oral cavity squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb hypopharyngeal squamous cell carcinoma, stage ivb laryngeal squamous cell carcinoma, stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc hypopharyngeal squamous cell carcinoma, stage ivc laryngeal squamous cell carcinoma, stage ivc oral cavity squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma